Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Envafolimab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07266493Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Started Dec 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07266493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266493.